This week we thought it would be interesting to share insights on a topical issue from Deloitte's U.S. Center for Health Solutions. This “My Take” from the January 20th, 2015 Health Care Current written by Homi Kapadia, Vice Chairman, U.S Life Sciences Leader, Deloitte LLP, provides a view on the rise of "pure play" business strategies for life science companies.[i]
Few can avoid the escalating hysteria of media headlines declaring that the NHS is yet again in the grip of another winter crisis, seemingly due to the sheer increase in volume of attendances at major Accident and Emergency (A&E) units. However, the facts of the matter are, that there is nothing unprecedented or unexpected about the level of A&E attendances, so what is behind the sharp fall in performance?
Deloitte’s 4th Annual Chief Procurement Officer (CPO) global survey results, released last month, highlights the key challenges faced by procurement leaders. A total of 239 CPOs participated from over 11 different industries, spread across 25 countries, including 22 working in the Healthcare and Life Science (HCLS) sector. Survey answers from HCLS CPOs show a number of notable differences from the cross industry responses.
The past year has been one of continued and unrelenting challenges for the NHS with healthcare dominating the news and public policy agenda throughout 2014.
As our final ‘Thought for the week’ of 2014, I thought I’d share with you the “My Take”,first published in the US Center for Health Solutions December 9, 2014 Health Care Current. Written by Pete Mooney, the Deloitte DTTL Global Managing Director for health care and life sciences, it presents his main takeaways from the November 2014 Financial Times Pharmaceutical and Biotechnology Conference (Watch the on demand videos from the conference including Joseph Jimenez, CEO Novartis, Simon Stevens and many more):
This week we launched our latest annual report on ‘Measuring the return from pharmaceutical innovation’ . Since 2010, we have been measuring the projected returns that the leading 12 life science companies are likely to deliver from the drugs they are developing in their late stage pipelines.
This week I was privileged to participate in a conference celebrating ten years of digital storytelling at which a book, ‘Cultivating Compassion – How digital storytelling is transforming healthcare’, was launched.[i] [ii]
This week I am delighted to introduce a guest ‘Thoughts from the Centre’ blog from Professor Nick Bosanquet, Emeritus Professor of Health Policy at Imperial College London:
On Monday 17 November 2014 we launched our latest report, Healthcare and Life Sciences Predictions 2020, at the FT Global Pharmaceuticals and Biotechnology Conference 2014 in London. This report is markedly different to our usual reports which are typically evidenced based with deep dives into specific issues. Instead, in this forward look, we provide a deliberately challenging view of what the industry might look like in 2020. The report is based on insights drawn from primary research, desk research and our day to day interactions with clients and key stakeholders across the sector, and utilises the breadth and depth of our experience across our global network. Two cross-cutting themes link the ten predictions, the revolutionary potential for digital technology and the evolutionary influence of patient power.
In May 2014, Public Health England and the Alzheimer’s Society, as part of the Prime Ministers Dementia Challenge, joined forces to launch a new campaign to encourage people to become Dementia Friends. Dementia Friends is a social movement which aims to create one million "Dementia Friends" by 2015. Currently there are over 500,000 Dementia Friends in the UK. This week, Deloitte’s entire Executive became Dementia Friends and, in leading by example, hope to boost the number by encouraging other Deloitte employees, and hopefully their clients, to follow suit.